AusperBio has raised $37m in a Series A financing round to propel the clinical development of AHB-1 for chronic hepatitis B (CHB).
The funding round was spearheaded by existing investor the InnoPinnacle Fund and saw contributions from new investors Qiming Venture Partners, Yuanbio Venture Capital, Hankang Capital and Genesis Capital.
The infusion of capital will be instrumental in furthering the clinical trials of AHB-137 and enhancing AusperBio’s Med-Oligo technology platform and its pipeline products.
The platform is integral to the company’s strategy to improve antisense oligonucleotide (ASO) therapeutics across disease categories including viral infections, metabolic diseases, genetic disorders and immune-related conditions.
AusperBio previously gained breakthrough therapy designation in China for AHB-137 to expedite the development and review process for the therapy.
AHB-137 is an unconjugated ASO therapy originating from the company’s med-oligo technology. It has been engineered specifically to target CHB to achieve a functional cure.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
The therapy is undergoing a Phase Ib trial in several international locations alongside a Phase II trial in China.
AusperBio co-founder and CEO Dr Guofeng Cheng stated: “This financing round represents a significant milestone that recognises our scientific and clinical achievements to date.
“The shared commitment from our investors to developing new therapeutics for CHB patients is truly inspiring.
“With this funding, together with the recent breakthrough therapy designation from China’s CDE [Centre for Drug Evaluation], we are well-positioned to rapidly advance the clinical development of AHB-137 and move closer to providing a vital new treatment option for patients with CHB.”
AusperBio’s med-oligo ASO platform leverages targeted delivery conjugation technologies to offer a modular approach that could revolutionise treatment options for a wide spectrum of diseases.
The company’s global development strategy is designed to fast-track AHB-137 as a potential cure for CHB.
